成都康华生物制品股份有限公司 | 非经营性资金占用 | | 资金占用 | | 占用方与上 市公司的关 | | 上市公司核算 | 2025 | 年期初 占用资金余 | 2025 | 年半年度 占用累计发生 | | 年半年 2025 度占用资金的 | | 2025 度偿还累计 | 年半年 | | | 年半年 2025 占用形成 度期末占用 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 方名称 | | 联关系 | | 的会计科目 | | 额 | | 金额（不含利 息） | | 利息（如有） | | 发生金额 | | | | 原因 资金余额 | | 控股股东、实际控制人及 | - | | - | | - | | - | | - | | - | | - | | | - | | - - | | 其附属企业 | - | | - | | - | | - | | - | | - | | - | | | - | | - ...

证券代码：300841 证券简称：康华生物 公告编号：2025-050 成都康华生物制品股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及《深圳 证券交易所创业板上市公司自律监管指南第 2 号——公告格式》的相关规定，成 都康华生物制品股份有限公司（以下简称"公司"）就 2025 年半年度募集资金 存放与使用情况作如下专项报告： 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 公司经中国证券监督管理委员会证监许可[2020]521 号《关于核准成都康华 生物制品股份有限公司首次公开发行股票的批复》核准，首次公开发行人民币普 通股（A 股）1,500.00 万股，每股发行价为人民币 70.37 元，发行新股 1,500.00 万股，共募集资金总额为人民币 105,555.00 万元，扣除各项发行费用人民币 7,457.70 万元后，募集资金净额为人民币 9 ...

2 0 24年 度 环 境 、 社 会 （E 2 0 24 E N VIR O N M E N T A L, S O CIAL A ND C O R P O R A TE G O V E R N A N CE ( E S G) R E P O R T | 股东权益保护 | 17 | | --- | --- | | 利益相关方 | 17 | | 企业荣誉 | 19 | | 4.可持续发展管理 | 23 | | 可持续发展管理策略 | 23 | | 可持续发展管理理念 | 23 | | 实质性议题分析 | 23 | | ESG治理架构 | 25 | | 董事会声明 | 26 | 成 都 康 华 生 物 制 品 股 份 有 限 公 司 CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD 地址：四川省成都经济技术开发区北京路182号 邮编：610100 电话：028-84846555（总机）或028-84882755 传真： （86）028-84846577 公司官网： www.kangh.com 邮箱：contact@kangh.com 2 0 2 4 及 公 司 治 理 S ...

本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届监事会第七次会 议通知已于2025年8月12日以电邮和专人通知方式向全体监事发出。会议于2025 年8月22日以现场与线上会议相结合方式召开。会议由监事会主席吴淑青女士召 集并主持，会议应出席监事3名，实际出席监事3名。本次会议的召集、召开程序 符合《中华人民共和国公司法》等法律、法规、规范性文件和《成都康华生物制 品股份有限公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 证券代码：300841 证券简称：康华生物 公告编号：2025-046 成都康华生物制品股份有限公司 第三届监事会第七次会议决议公告 经与会监事认真讨论，审议并通过如下议案： （一） 审议通过《关于2025年半年度报告及其摘要的议案》 公司编制和审核2025年半年度报告及其摘要的程序符合法律、行政法规、中 国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（www. ...

证券代码：300841 证券简称：康华生物 公告编号：2025-045 成都康华生物制品股份有限公司 第三届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届董事会第七次 会议通知于2025年8月12日以电邮和专人通知的方式向全体董事和监事发出，会 议于2025年8月22日以现场与线上会议相结合方式召开。本次会议由董事长王振 滔先生召集并主持，会议应出席董事8人，实际出席董事8人，公司监事、高级管 理人员列席了本次会议。本次会议的召集和召开程序符合《中华人民共和国公司 法》、《成都康华生物制品股份有限公司章程》等有关规定，会议合法、有效。 二、 董事会会议审议情况 （一）审议通过《关于 2025 年半年度报告及其摘要的议案》 公司 2025 年半年度报告编制和审核的程序符合相关法律法规，报告内容真 实、准确、完整地反映了公司 2025 年半年度经营的实际情况，不存在虚假记载、 误导性陈述或重大遗漏。 本议案已经第三届董事会审计委员会第四次会议审议通过。 具体 ...

成都康华生物制品股份有限公司 2025 年半年度报告全文 公司代码：300841 公司简称：康华生物 成都康华生物制品股份有限公司 2025 年半年度报告 2025-048 2025 年 8 月 1 成都康华生物制品股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人王振滔、主管会计工作负责人吴文年及会计机构负责人(会计 主管人员)刘萍声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公 司对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素： 1、产品研发不达预期的风险 疫苗产品具有研发周期长、技术难度大、研发风险高等特点，同时考虑 到外部环境因素的变化，疫苗产品研发成果能否顺利实现规模化 ...

Core Viewpoint - The stock market is experiencing a bullish trend, with the Shanghai Composite Index surpassing 3700 points, while a notable increase in shareholding reduction announcements from major shareholders of listed biopharmaceutical companies is observed [1] Company Summaries - Over 30 biopharmaceutical companies have announced shareholder reduction plans since August 1, with several companies reducing their holdings by 3% or more [1][2] - Key companies with significant shareholder reductions include: - Linuo Pharmaceutical: 840.73 thousand shares (3.61%) - Kangtai Medical: 1,441.6 thousand shares (3.59%) - Shengyin Meisi: 509.45 thousand shares (3.04%) - Chenxin Pharmaceutical: 1,358.26 thousand shares (3.95%) - Ailis: 1,350 thousand shares (3%) - Kanghua Biological: 389.84 thousand shares (3%) [2] - Kanghua Biological's major shareholder, Sichuan Development Securities Investment Fund Management Co., plans to reduce its holdings by up to 3,898,405 shares (3% of total shares) within three months [3] - The company has faced a decline in performance, with a 43.83% drop in the issuance of its main product, the freeze-dried human rabies vaccine, leading to a 9.23% decrease in revenue to 1.432 billion yuan and a 21.71% drop in net profit to 399 million yuan in 2024 [5] - The competitive landscape for rabies vaccines is intensifying, with new entrants like Shenzhen Kangtai Biological Products Co. launching similar products, which may further challenge Kanghua Biological's market position [5][6]

Group 1 - The animal vaccine sector experienced a decline of 0.72% as of the market close on August 22, ranking among the top declines in concept sectors [1] - Within the animal vaccine sector, companies such as Shenlian Biological, Weilan Biological, and Xianfeng Holdings saw significant declines, while Kexing Pharmaceutical, Haizheng Pharmaceutical, and Guoyao Modern recorded increases of 2.06%, 0.44%, and 0.09% respectively [1] - The overall market saw a net outflow of 0.68 billion yuan from the animal vaccine sector, with 11 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net outflow in the animal vaccine sector was from Kanghua Biological, with a net outflow of 30.50 million yuan, followed by Shenlian Biological, Dabeinong, and Jinhai Biological with outflows of 27.38 million yuan, 24.27 million yuan, and 23.53 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Luoniushan, with net inflows of 27.34 million yuan, 16.70 million yuan, and 10.38 million yuan respectively [3] - The trading activity in the animal vaccine sector showed that Kanghua Biological had a turnover rate of 3.52% and a decline of 1.70%, while Kexing Pharmaceutical had a turnover rate of 3.12% and an increase of 2.06% [3]

Group 1 - The latest stock price of Kanghua Biotech is 86.24 yuan, an increase of 2.54 yuan or 3.03% from the previous trading day. The intraday high reached 87.52 yuan and the low was 83.70 yuan, with a trading volume of 527 million yuan and a turnover rate of 5.13% [1] - Kanghua Biotech operates in the biopharmaceutical sector, focusing on the research, production, and sales of human vaccines. Its main products include rabies vaccines and Japanese encephalitis vaccines, and the company is actively expanding into the pet vaccine market [1] - The Shanghai Biopharmaceutical M&A Fund strategically took control of Kanghua Biotech in July, with plans to accelerate the diversification of the vaccine product line and build a vaccine ecosystem. This collaboration is seen as a significant move by Shanghai state-owned assets in the biopharmaceutical field [1] Group 2 - On August 21, Kanghua Biotech experienced a net inflow of 37.11 million yuan in main funds, accounting for 0.36% of its circulating market value. However, over the past five days, there was a net outflow of 114 million yuan, representing 1.11% of its circulating market value [1]

Group 1 - The stock price of Kanghua Biotech is reported at 85.99 yuan as of August 19, 2025, showing a decline of 1.35% from the previous trading day with a trading volume of 650 million yuan [1] - The company operates in the biopharmaceutical industry, focusing on the research, production, and sales of vaccines and biological products, primarily in human and pet vaccine sectors, with a market presence in both domestic and some overseas regions [1] - On the morning of August 19, the stock experienced a rapid decline around 9:47 AM, dropping over 2% within 5 minutes, reaching a low of 88.22 yuan with a transaction volume of 178 million yuan [1] Group 2 - On August 19, the net outflow of main funds was 56.87 million yuan, accounting for 0.56% of the circulating market value, with a cumulative net outflow of 9.80 million yuan over the past five trading days [1]